Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer

Cell chemical biology(2021)10.1016/j.chembiol.2021.08.011Source: DataRank Database

Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer is a research paper published in Cell chemical biology (2021). On theSindex it has a DataRank of 0. It has been cited 22 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access22 citations

Download PDF

Cite:

Linked data & code

gen nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 2.14)OA: greenTopics (29)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Michelle Velyunskiy,Sara F. Dunne ORCID,Byoung-Kyu Cho ORCID,Deepak Kanojia ORCID,Lauren R. Begg ORCID

Live enrichment

PubMed:34525344 PMC:PMC8901784 OpenAlex:https://openalex.org/W3201181805

National Cancer Institute

Grant: S10OD025194

National Cancer Institute

Grant: CCSG P30 CA060553

National Center for Advancing Translational Sciences

Grant: UL1TR001422

US Department of Defense

Grant: W81XWH1810053

NIH

Grant: P41 GM108569

Susan G Komen Breast Cancer Foundation

Grant: CCR17488145

Susan G Komen Breast Cancer Foundation

Grant: CCR16376693

NIGMS NIH HHS

Grant: T32 GM008061

NCI NIH HHS

Grant: P30 CA060553

NIH HHS

Grant: S10 OD023681

FWCI

2.14

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8901784

BRONZEhttps://doi.org/10.1016/j.chembiol.2021.08.011

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8901784

publisherhttps://api.elsevier.com/content/article/PII:S2451945621004001?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2451945621004001?httpAccept=text/plain

Fields of Study

Cancer Mechanisms and TherapyPeptidase Inhibition and AnalysisCancer therapeutics and mechanismsMedicine

MeSH Terms

HumansCell Line, TumorProteasome Endopeptidase ComplexProtein Kinase InhibitorsCell ProliferationProto-Oncogene Proteins c-pim-1Triple Negative Breast Neoplasms

Keywords

Triple-negative breast cancerProteasomeCancer researchBreast cancerKinaseProteasome inhibitorCancerMedicineBiologyInternal medicineCell biologychemical geneticsProteasome inhibitorsProtein HomeostasisPim Kinase InhibitorProteotoxic StressMyc OncoproteinRational Combination Therapy

Sustainable Development Goals

SDG 0: No poverty